In favor of this, preclinical models involving inhibition of CCL2 (Flores-Toro et al, 2020), NOS2 (Jacquelot et al, 2019), and LCN2 (Leng et al, 2009) pathways have shown anti-tumor effects and may be explored to improve IL6 inhibitory strategies after PD-L1 treatment failure. The gene discussed is IL6; the disease is neoplasm.